Global BCG Vaccine Market to 2030 – Opportunity Analysis and Industry Forecasts –

Global BCG Vaccine Market to 2030 – Opportunity Analysis and Industry Forecasts –

Global BCG Vaccine Market to 2030 – Opportunity Analysis and Industry Forecasts –

DUBLIN–(BUSINESS WIRE)–The “BCG Vaccine Market by Demographics (Pediatric and Adults: Global Opportunity Analysis and Industry Forecast, 2021-2030” report has been added to’s offering.

The global BCG vaccine market was valued at $46,637.5 thousands in 2020, and is projected to reach $74,269.55 thousands by 2030, registering a CAGR of 4.8% from 2021 to 2030.

Bacillus Calmette-Guerin (BCG) vaccine is the only vaccine available for the prevention of human forms of tuberculosis (TB). This vaccine is generally administered to children at birth in countries with high incidence of TB. In regions with low level of TB, only children at high risk are typically immunized, whereas adults are generally not immunized. However, adults (up to the age of 35) who are frequently exposed to drug-resistant TB may also be given BCG vaccine.

The global BCG vaccine market is driven by increase in prevalence of tuberculosis and rise in technological advancements in vaccine research. Moreover, the increase in government initiatives and focus on immunization programs globally boost the market growth. However, side effects of BCG vaccine and the global shortage of BCG vaccine restrain this growth. Untapped market potential in developing regions are expected to present numerous opportunities for market development during the forecast period.

The BCG vaccine market is segmented on the basis of demographics, and region. On the basis of demographics, it is bifurcated into pediatrics (0-18 Years) and Adults (19-35 years). Region wise, the market is analyzed across Asia-Pacific, LAMEA, and Rest of the World.

Key Benefits

  • This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2030, which assists to identify the prevailing market opportunities
  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans
  • A comprehensive analysis of the factors that drive and restrain the growth of the BCG vaccine market is provided
  • An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves

Key Segments

By Demographic Type

  • Pediatrics (0-18 Years)
  • Adults (19-35 Years)

By Region

  • Asia Pacific
  • India
  • China
  • Bangladesh
  • Pakistan
  • Indonesia
  • Japan
  • Thailand
  • Singapore
  • Rest of Asia-Pacific
  • Brazil
  • Mexico
  • South Africa
  • Kenya
  • Argentina
  • Colombia
  • Chile
  • Rest of LAMEA

Key Players

  • AJ Biologics
  • China National group corporation (Sinopharm)
  • Greensignal Biopharma Limited
  • Intervax Ltd
  • Japan BCG Laboratory
  • Merck & Co, Inc
  • Sanofi
  • Serum Institute of India Pvt Ltd
  • Stetens Serum Institute
  • Torlak Institute of Virology

For more information about this report visit


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900